Novel immunotherapeutic approaches to the treatment of infections caused by Gram-negative bacteria

Soumya Palliyil, Ian D Broadbent

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

The rise in infections caused by Gram-negative bacteria and the spread of resistance to conventional antibiotics provide significant challenges to the pharmaceutical industry. Monoclonal antibodies have achieved impressive recent clinical successes in a variety of indications, but to date there are no licensed immunotherapeutics that target bacterial infections, despite several promising studies in animal models of infection. Several key questions remain, in particular relating to the target(s), mechanism of action, and mode of delivery of any potential novel immunotherapeutic. This short review discusses recent approaches being taken to develop novel immunotherapeutic molecules for the treatment of Gram-negative bacterial infections.

Original languageEnglish
Pages (from-to)566-570
Number of pages5
JournalCurrent Opinion in Pharmacology
Volume9
Issue number5
DOIs
Publication statusPublished - Oct 2009

Fingerprint

Gram-Negative Bacteria
Gram-Negative Bacterial Infections
Drug Industry
Infection
Bacterial Infections
Animal Models
Monoclonal Antibodies
Anti-Bacterial Agents

Keywords

  • animals
  • anti-bacterial agents
  • antibodies, monoclonal
  • antigens, bacterial
  • bacterial vaccines
  • drug design
  • drug resistance, bacterial
  • gram-negative bacteria
  • gram-negative bacterial infections
  • humans
  • immunotherapy
  • treatment outcome

Cite this

Novel immunotherapeutic approaches to the treatment of infections caused by Gram-negative bacteria. / Palliyil, Soumya; Broadbent, Ian D.

In: Current Opinion in Pharmacology, Vol. 9, No. 5, 10.2009, p. 566-570.

Research output: Contribution to journalArticle

@article{41f2558f614945ceb56d0dacdc3db69f,
title = "Novel immunotherapeutic approaches to the treatment of infections caused by Gram-negative bacteria",
abstract = "The rise in infections caused by Gram-negative bacteria and the spread of resistance to conventional antibiotics provide significant challenges to the pharmaceutical industry. Monoclonal antibodies have achieved impressive recent clinical successes in a variety of indications, but to date there are no licensed immunotherapeutics that target bacterial infections, despite several promising studies in animal models of infection. Several key questions remain, in particular relating to the target(s), mechanism of action, and mode of delivery of any potential novel immunotherapeutic. This short review discusses recent approaches being taken to develop novel immunotherapeutic molecules for the treatment of Gram-negative bacterial infections.",
keywords = "animals, anti-bacterial agents, antibodies, monoclonal, antigens, bacterial, bacterial vaccines, drug design, drug resistance, bacterial, gram-negative bacteria, gram-negative bacterial infections, humans, immunotherapy, treatment outcome",
author = "Soumya Palliyil and Broadbent, {Ian D}",
year = "2009",
month = "10",
doi = "10.1016/j.coph.2009.07.007",
language = "English",
volume = "9",
pages = "566--570",
journal = "Current Opinion in Pharmacology",
issn = "1471-4892",
publisher = "Elsevier BV",
number = "5",

}

TY - JOUR

T1 - Novel immunotherapeutic approaches to the treatment of infections caused by Gram-negative bacteria

AU - Palliyil, Soumya

AU - Broadbent, Ian D

PY - 2009/10

Y1 - 2009/10

N2 - The rise in infections caused by Gram-negative bacteria and the spread of resistance to conventional antibiotics provide significant challenges to the pharmaceutical industry. Monoclonal antibodies have achieved impressive recent clinical successes in a variety of indications, but to date there are no licensed immunotherapeutics that target bacterial infections, despite several promising studies in animal models of infection. Several key questions remain, in particular relating to the target(s), mechanism of action, and mode of delivery of any potential novel immunotherapeutic. This short review discusses recent approaches being taken to develop novel immunotherapeutic molecules for the treatment of Gram-negative bacterial infections.

AB - The rise in infections caused by Gram-negative bacteria and the spread of resistance to conventional antibiotics provide significant challenges to the pharmaceutical industry. Monoclonal antibodies have achieved impressive recent clinical successes in a variety of indications, but to date there are no licensed immunotherapeutics that target bacterial infections, despite several promising studies in animal models of infection. Several key questions remain, in particular relating to the target(s), mechanism of action, and mode of delivery of any potential novel immunotherapeutic. This short review discusses recent approaches being taken to develop novel immunotherapeutic molecules for the treatment of Gram-negative bacterial infections.

KW - animals

KW - anti-bacterial agents

KW - antibodies, monoclonal

KW - antigens, bacterial

KW - bacterial vaccines

KW - drug design

KW - drug resistance, bacterial

KW - gram-negative bacteria

KW - gram-negative bacterial infections

KW - humans

KW - immunotherapy

KW - treatment outcome

U2 - 10.1016/j.coph.2009.07.007

DO - 10.1016/j.coph.2009.07.007

M3 - Article

VL - 9

SP - 566

EP - 570

JO - Current Opinion in Pharmacology

JF - Current Opinion in Pharmacology

SN - 1471-4892

IS - 5

ER -